European drug association criticizes EU plan for disclosure rules

07/1/2013 | Chemical & Engineering News

The European Federation of Pharmaceutical Industries and Associations said that proposals by the European Medicines Agency to make clinical trial data public could compromise sensitive proprietary research and place their companies at a competitive disadvantage. The EMA draft plan, scheduled to go into effect by Jan. 1, is open for three months of comments. The federation says it is preparing its own alternative for publishing trial results.

View Full Article in:

Chemical & Engineering News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Fort Worth, TX
Senior Scientist - Cell Engineering Group
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC